Daniela M. Ferreira | |
---|---|
Born | Daniela M. Ferreira |
Citizenship | Brazilian and British |
Education | University of São Paulo (SP) University of São Paulo (PhD) |
Known for | Research on Respiratory Infections and Covid-19 Vaccine trials |
Scientific career | |
Fields | Respiratory tract infection, Vaccine and Immunology |
Institutions | University of Oxford Liverpool School of Tropical Medicine Butantan institute |
Thesis | DNA vaccines against Streptococcus pneumoniae based on PspA (Pneumococcal surface protein A) and PspC (Pneumococcal surface protein C) (2009) |
Daniela M. Ferreira is a Brazilian British immunologist. [1] She is a specialist in bacterial infection, respiratory co-infection, mucosal immunology and vaccine responses. She is currently Professor of Respiratory Infection and Vaccinology at the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and the Director of the Liverpool Vaccine Group at the Liverpool School of Tropical Medicine. [2] [3] She leads a team of scientists studying protective immune responses against pneumococcus [4] and other respiratory pathogens such as SARS-CoV2. Her team has established a novel method of inducing pneumococcal carriage in human volunteers. [4] They use this model to:
Her team has played a substantial role in the UK covid-19 pandemic response as a trial site for several COVID-19 vaccine studies including the Oxford / Astrazeneca vaccine. [5] [6] [7]
Ferreira is part of the HIC-VAC consortium [8] and Leads the WorkStream on Human Challenge Plataform to accelerate product development in the UKRI Infection Innovation Consortium (iiCON). [9]
Ferreira obtained a Degree and Bachelor's Degree in Biological Sciences in 2005 and a Ph.D. in Immunology in 2009, both from the University of São Paulo (São Paulo, Brazil). During her PhD, Ferreira was awarded the Robert Austrian Research Award in Pneumococcal Vaccinology. [10]
Ferreira joined the Respiratory Infection group at Liverpool School of Tropical Medicine as a postdoctoral fellow in December 2009 and together with Prof. Stephen Gordon led the development of an Experimental Human Pneumococcal Nasopharyngeal Colonization Model. Ferreira was appointed Professor and subsequent Head of Department of Clinical Sciences in 2018. [2] Her main lines of research are:
Pleural empyema is a collection of pus in the pleural cavity caused by microorganisms, usually bacteria. Often it happens in the context of a pneumonia, injury, or chest surgery. It is one of the various kinds of pleural effusion. There are three stages: exudative, when there is an increase in pleural fluid with or without the presence of pus; fibrinopurulent, when fibrous septa form localized pus pockets; and the final organizing stage, when there is scarring of the pleura membranes with possible inability of the lung to expand. Simple pleural effusions occur in up to 40% of bacterial pneumonias. They are usually small and resolve with appropriate antibiotic therapy. If however an empyema develops additional intervention is required.
Lymphangioleiomyomatosis (LAM) is a rare, progressive and systemic disease that typically results in cystic lung destruction. It predominantly affects women, especially during childbearing years. The term sporadic LAM is used for patients with LAM not associated with tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that is associated with TSC.
Sexual characteristics are physical traits of an organism which are indicative of or resultant from biological sexual factors. These include both primary sex characteristics, such as gonads, and secondary sex characteristics.
Pneumococcal pneumonia is a type of bacterial pneumonia that is caused by Streptococcus pneumoniae (pneumococcus). It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases.
Pleural thickening is an increase in the bulkiness of one or both of the pulmonary pleurae.
Löfgren syndrome is a type of acute sarcoidosis, an inflammatory disorder characterized by swollen lymph nodes in the chest, tender red nodules on the shins, fever and arthritis. It is more common in women than men, and is more frequent in those of Scandinavian, Irish, African and Puerto Rican heritage. It was described in 1953 by Sven Halvar Löfgren, a Swedish clinician. Some have considered the condition to be imprecisely defined.
Idiopathic interstitial pneumonia (IIP), or noninfectious pneumonia are a class of diffuse lung diseases. These diseases typically affect the pulmonary interstitium, although some also have a component affecting the airways. There are seven recognized distinct subtypes of IIP.
Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer and breast cancer account for about 50-65% of malignant pleural effusions. Other common causes include pleural mesothelioma and lymphoma.
Dynein axonemal heavy chain 5 is a protein that in humans is encoded by the DNAH5 gene.
HLA-B7 (B7) is an HLA-B serotype. The serotype identifies the more common HLA-B*07 gene products. B7, previously HL-A7, was one of the first 'HL-A' antigens recognized, largely because of the frequency of B*0702 in Northern and Western Europe and the United States. B7 is found in two major haplotypes in Europe, where it reaches peak frequency in Ireland. One haplotype A3-B7-DR15-DQ1 can be found over a vast region and is in apparent selective disequilibrium. B7 is a risk factor for cervical cancer, sarcoidosis, and early-onset spondylarthropathies.
Ventilator-associated lung injury (VALI) is an acute lung injury that develops during mechanical ventilation and is termed ventilator-induced lung injury (VILI) if it can be proven that the mechanical ventilation caused the acute lung injury. In contrast, ventilator-associated lung injury (VALI) exists if the cause cannot be proven. VALI is the appropriate term in most situations because it is virtually impossible to prove what actually caused the lung injury in the hospital.
Pulmonary hygiene, also referred to as pulmonary toilet, is a set of methods used to clear mucus and secretions from the airways. The word pulmonary refers to the lungs. The word toilet, related to the French toilette, refers to body care and hygiene; this root is used in words such as toiletry that also relate to cleansing.
Bronchial hyperresponsiveness is a state characterised by easily triggered bronchospasm.
Airway pressure release ventilation (APRV) is a pressure control mode of mechanical ventilation that utilizes an inverse ratio ventilation strategy. APRV is an applied continuous positive airway pressure (CPAP) that at a set timed interval releases the applied pressure. Depending on the ventilator manufacturer, it may be referred to as BiVent. This is just as appropriate to use, since the only difference is that the term APRV is copyrighted.
Hypothiocyanite is the anion [OSCN]− and the conjugate base of hypothiocyanous acid (HOSCN). It is an organic compound part of the thiocyanates as it contains the functional group SCN. It is formed when an oxygen is singly bonded to the thiocyanate group. Hypothiocyanous acid is a fairly weak acid; its acid dissociation constant (pKa) is 5.3.
The respiratory tract antimicrobial defense system is a layered defense mechanism which relies on components of both the innate and adaptive immune systems to protect the lungs and the rest of the respiratory tract against inhaled microorganisms.
Inverse ratio ventilation (IRV) is not necessarily a mode of mechanical ventilation though it may be referred to as such. IRV is a strategy of ventilating the lungs in such a way that the amount of time the lungs are in inhalation is greater than the amount of time they are in exhalation, allowing for a constant inflation of the lungs, ensuring they remain "recruited". The primary goal for IRV is improved oxygenation by forcing inspiratory time to be greater than expiratory time increasing the mean airway pressure and potentially improving oxygenation. Normal I:E ratio is 5:6, so forcing the I:E to be 2:1, 3:1, 4:1, is the source of the term for the strategy.
Fosfomycin/tobramycin is a formulation of fosfomycin and tobramycin. Fosfomycin is a phosphonic acid antibiotic active against gram-positive and gram-negative. Tobramycin is an aminoglycoside with gram-negative activity. It is an inhaled medication targeting those with cystic fibrosis and is currently being studied by Gilead Sciences the United States Food and Drug Administration and the NIH General Clinical Research Center.
Daniel Michael Musher is an American physician, scientist, and medical educator working in the field of infectious diseases, who has coauthored more than 600 publications. Musher is a Distinguished Service Professor of Medicine and Professor of Molecular Virology and Microbiology at the Baylor College of Medicine in Houston, Texas.
A human challenge study, also called a challenge trial or controlled human infection model (CHIM), is a type of clinical trial for a vaccine or other pharmaceutical involving the intentional exposure of the test subject to the condition tested. Human challenge studies may be ethically controversial because they involve exposing test subjects to dangers beyond those posed by potential side effects of the substance being tested. Controlled human infection studies are also used to study viruses and immune responses.